PyInvesting

Market research

TXG 10X Genomics Inc

NASDAQ USD Healthcare

Latest close

Loading market data…

Test a moving-average rule with historical data.

Market cap
8B
P/E ratio
Not available
Analyst target
49.5385
Dividend yield
Not available
Beta
2.04

Community

Investor discussion

1 comment

Admin profile picture
Admin

5 years, 4 months ago

10x Genomics, Inc is currently in a long term uptrend where the price is trading 12.7% above its 200 day moving average.

From a valuation standpoint, the stock is 95.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 64.6.

10x Genomics, Inc's total revenue rose by 49.0% to $112M since the same quarter in the previous year.

Its net income has dropped by 5725.2% to $-416M since the same quarter in the previous year.

Finally, its free cash flow grew by 59911.6% to $71M since the same quarter in the previous year.

Based on the above factors, 10x Genomics, Inc gets an overall score of 4/5.